JIMANDIN FILM-COATED TABLETS 100MG

MEDOCHEMIE (FAR EAST) LTD ORAL FACILITY (VIETNAM SOC REP OF)🇸🇬 Health Sciences Authority

Approval Date: Jun 26, 2025
Approval ID: ba894f58a6827a5e
Company: MEDOCHEMIE (FAR EAST) LTD ORAL FACILITY (VIETNAM SOC REP OF)
Type: Therapeutic

Approval Details

Approval Id: ba894f58a6827a5e
Drug Name: JIMANDIN FILM-COATED TABLETS 100MG
Product Name: JIMANDIN FILM-COATED TABLETS 100MG
Approval Number: SIN17267P
Approval Date: 2025-06-26
Registrant: MEDOCHEMIE SINGAPORE PTE. LTD.
Licence Holder: MEDOCHEMIE SINGAPORE PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: TABLET, FILM COATED
Dosage: 4.2 Posology and method of administration Recommended Dosing The recommended dose of SITAGLIPTIN is 100 mg once daily. SITAGLIPTIN can be taken with or without food. Patients with Renal Impairment Because there is a dosage adjustment based upon renal function, assessment of renal function is recommended prior to initiation of SITAGLIPTIN and periodically thereafter. For patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 to < 90 mL/min/1.73 m2), no dosage adjustment for SITAGLIPTIN is required. For patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 to < 60 mL/min/1.73 m2), no dosage adjustment for SITAGLIPTIN is required. For patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 to < 45 mL/min/1.73 m2), the dose of SITAGLIPTIN is 50 mg once daily. For patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 to < 30 mL/min/1.73 m2) or with end-stage renal disease (ESRD) (eGFR < 15 mL/min/1.73 m2), including those requiring hemodialysis or peritoneal dialysis, the dose of SITAGLIPTIN is 25 mg once daily. SITAGLIPTIN may be administered without regard to the timing of dialysis. Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin When SITAGLIPTIN is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to reduce the risk of hypoglycemia. [See Warnings and Precautions (4.4) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]
Route Of Administration: ORAL
Indication Info: 4.1 Therapeutic indications Monotherapy SITAGLIPTIN is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Combination with Metformin SITAGLIPTIN is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a Sulfonylurea SITAGLIPTIN is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a PPARγ agonist SITAGLIPTIN is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a PPARγ agonist (e.g., thiazolidinediones) when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with Metformin and a Sulfonylurea SITAGLIPTIN is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control. Combination with Insulin SITAGLIPTIN is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycemic control. Important Limitations of Use SITAGLIPTIN should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. SITAGLIPTIN has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using SITAGLIPTIN. [See Warnings and Precautions (4.4) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]
Contraindications: 4.3 Contraindications History of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema. [See Warnings and Precautions (4.4); Adverse Reactions (4.8) – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information]

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Jun 26, 2025

Approval ID

ba894f58a6827a5e

Type

Therapeutic

Back to HSA Approvals